← Back to Search

89Zr- DFO-MSTP2109A for Prostate Cancer

Phase 1 & 2
Waitlist Available
Led By Steven Larson, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new agent, 89Zr-DFO-MSTP2109A, to see if it can be used to find prostate cancer tumors with a PET scan. The agent is an antibody that works against STEAP1, which is found on the surface of prostate cancer cells. If successful, the agent could be used in the future to help diagnose prostate cancer and to help guide new therapies.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Serial blood draws will be used to estimate the pharmacokinetics (PK)
biodistribution
feasibility
+1 more
Secondary outcome measures
ability of 89Zr-DFO-MSTP2109A PET to detect sites of metastatic prostate cancer.

Trial Design

2Treatment groups
Experimental Treatment
Group I: 89Zr-DFO-MSTP2109A tracer Group 2Experimental Treatment1 Intervention
Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
Group II: 89Zr DFOMSTP2109A tracer Group 1Experimental Treatment1 Intervention
The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
89Zr- DFO-MSTP2109A
2013
Completed Phase 2
~20
89Zr DFO-MSTP2109A
2013
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Genentech, Inc.Industry Sponsor
1,538 Previous Clinical Trials
567,709 Total Patients Enrolled
16 Trials studying Prostate Cancer
6,191 Patients Enrolled for Prostate Cancer
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,360 Total Patients Enrolled
132 Trials studying Prostate Cancer
52,055 Patients Enrolled for Prostate Cancer
Steven Larson, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
35 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical trial taking on new participants at the moment?

"According to the clinicaltrials.gov website, this study is no longer recruiting for participants. It was first published on January 1st 2013 and last updated on February 3rd 2022. However, there are a plethora of other studies seeking volunteers at present; 1315 trials in total."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
2013. "Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01774071.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top